Novel therapeutic targets in Helicobacter pylori

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 6, 2003, Pages 725-735

  Loughlin, Michael F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Genomics; Helicobacter pylori; Novel targets; Proteomics; Transcriptomics; Vaccine

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH DERIVATIVE; CARCINOGEN; CEFIXIME; CLARITHROMYCIN; GENE PRODUCT; HELICOBACTER PYLORI VACCINE; LANSOPRAZOLE; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; SECNIDAZOLE; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; DRUG TARGETING; DRUG TRANSPORT; ERADICATION THERAPY; GASTRITIS; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFORMATION PROCESSING; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PREVALENCE; PROTEOMICS; REVIEW; TREATMENT FAILURE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CARRIER STATE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GASTRITIS; GENE EXPRESSION PROFILING; GENES, BACTERIAL; GENES, REPORTER; GERBILLINAE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MUTAGENESIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIC ULCER; PROTEIN INTERACTION MAPPING; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMACH NEOPLASMS; VIRULENCE;

EID: 0346957064     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.6.725     Document Type: Review

References (79)

1. SEPULVEDA AR, COELHO LG: Helicobacter pylori and gastric malignancies. Helicobacter (2002) 7:37-42.
2. DUNN BE, COHEN H, BLASER MJ: Helicobacter pylori. Clin. Microbiol. Rev. (1997) 10:720-741.
3. GODDARD AF: Getting to the route of Helicobacter pylori treatment. J. Antimicrob. Chemother. (1998) 42:1-3.
4. BAZZOLI F, POZZATO P, ROKKAS T: Helicobacter pylori: the challenge in therapy. Helicobacter (2002) 7:43-49.
5. MÉGRAUD F: Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology (1998) 115:1278-1282.
6. VAN DER WOUDEN EJ, THIJIS JC, VANZWET AA, SLUITER WJ, KLEIBEUKER JH: The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol. (1999) 94:1751-1759.
7. AHUJA V, DHAR A, BAL C, SHARMA MP: Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment. Pharamcol. Ther. (1998) 12(6):551-555.
8. HORII T, MASE K, SUZUKI Y et al.: Antibacterial activities of β lactamase inhibitors associated with morphological changes of cell wall in Helicobacter pylori. Helicobacter (2002) 7(1):39-45.
9. OSATO MS, REDDY SG, PIERGIES AA, BOCHENEK WJ, TESTSA RT, GRAHAM DY: Comparative efficacy of new investigational agents against Helicobacter pylori. Aliment. Pharmacol. Ther. (2001) 15(4):487-492.
10. AKRITOPOULOU-ZANZE I, SOWIN TJ: Solid-phase synthesis of macrolide analogues. J. Comb. Chem. (2001) 3(3):301-311.
11. GISBERT JP, PAJARES JM, RACZ I: Therapy. Curr. Opin. Gastroenterol. (2001) 17:S47-S54.
12. 2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter (2003) 8(2):111-119.
13. 2-antagonist properties. Bioorg. Med. Chem. Lett. (2001)11(3):403-406.
14. GISBERT JP, CALVET X, BUJANDA L, MARCOS S, GISBERT JL, PAJAR JM: 'Rescue' therapy with rifabutin after multiple Helicobacter pylori failure. Helicobacter (2003) 8(2):90-94.
15. JENKS PJ: Helicobacter pylori: towards new therapeutic targets. J. Med. Microbiol. (2001) 50:485-488.
16. MACKAY WG, WILLIAMS CL, MCMILLAN M, NDIP RN, SHEPHERD AJ, WEAVER LT: Evaluation of protocol using gene capture and PCR for detection of Helicobacter pylori DNA in feces. J. Clin. Microbiol. (2003) 41(10):4589-4593.
17. LASCOLS C, LAMARQUE D, COSTA JM et al.: Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J. Clin. Microbiol. (2003) 41(10):4573-4577.
18. TOMB JF, WHITE O, KERLAVAGE AR et al.: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 388:539-547.
19. ALM RA, LING LS, MOIR DT et al.: Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature (1999) 397:176-180.
20. HUGHES D: Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Genet. (2003) 4:432-441.
21. BJORKHOLM BM, OH JD, FALK PG, ENGSTRAND LG, GORDON JI: Genomics and proteomics converge on Helicobacter pylori. Curr. Opin. Microbiol. (2001) 4:237-245.
22. PARKINSON T: The impact of genomics on anti-infectives drug discovery and development. Trends Microbiol. (2002) 10(10):S22-S26.
23. SALAMA N, GUILLEMIN K, MCDANIEL TK, SHERLOCK G, TOMPKINS L, FALKOW S: A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc. Natl. Acad. Sci. USA (2000) 97:14668-14673
24. PIZZA M, SCARLATO V, MASIGNANI V et al.: Identification of vaccine-candidates against serogroup B meningococcus by whole genome sequencing. Science (2000) 287:1816-1820.
25. MONTIGIANI S, FALUGI F, SCARSELLI M et al.: Genomic approach for the analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. (2002) 70:368-379.
26. GRANDI G: Rational antibacterial vaccine design through genomic technologies. Int. J. Parasitol. (2003) 33:615-620.
27. ALM RA, BINA J, ANDREWS BM, DOIG P, HANCOCK RE, TRUST TJ: Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families. Infect. Immun. (2000) 68:4155-4168.
28. THYE T, BURCHARD GD, NILIUS M, MULLER-MYSHOK B, HORSTMANN RD: Genomewide linkage analysis identifies polymorphism in the human interferon-γ receptor affecting Helicobacter pylori infection. Am. J. Hum. Genet. (2003) 72:448-453.
29. FIGUEIREDO C, MACHADO JC, PHAROAH P et al.: Helicobacter pylori and interleukin-1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. (2002) 94(22):1680-1687.
30. CHALKER AF, MINEHART HW, HUGHES NJ et al.: Systematic identification of selective essential genes in Helicobacter pylori by genome prioritisation and allelic replacement mutagenesis. J. Bacteriol. (2001) 183:1259-1268.
31. HENSEL M, SHEA JE, GLEESON C, JONES MD, DALTON E, HOLDEN DW: Simultaneous identification of bacterial virulence genes by negative selection. Science (1995) 269:400-403.
32. KAVERMANN H, BURNS B, ANGERMULLER K et al.: Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J. Exp. Med. (2003) 197(7):813-822.
33. GUO BP, MEKALANOS JJ: Rapid genetic analysis of Helicobacter pylori gastric mucosal colonization in suckling mice. Proc. Natl. Acad. Sci. USA (2002) 99(2):8354-8359.
34. WANG J, LORY S, RAMPHAL R, JIN S: Isolation and characterisation of Pseudomonas aeruginosa genes inducible by respiratory mucus derived from cystic fibrosis patients. Mol. Microbiol. (1996) 22(5):1005-1012.
35. STAIB P, KRETSCHMAR M, NICHTERLEIN T et al.: Host-induced, stage-specific virulence gene activation in Candida albicans during infection. Mol. Microbiol. (1999) 32(3):533-546.
36. SLAUCH JM, CAMILLI A: IVET and RIVET: the use of gene fusions to identify bacterial virulence factors specifically induced in host tissues. Methods Enzymol. (2000) 326:73-96.
37. MORISE M, SHIMOMURA O, JOHNSON FH, WINANT J: Intermolecular energy transfer in the bioluminescent system of Aequorea. Biochemistry (1974) 13:2656-2662.
38. MARRA A, ASUNDI J, BARTILSON M et al.: Differential fluorescence induction analysis of Streptococcus pneumoniae identifies genes involved in pathogenesis. Infect. Immun. (2002) 70(3):1422-1433.
39. BONGAERTS RJ, HAUTEFORT I, SIDEBOTHAM JM, HINTON JC: Green fluorescent protein as a marker for conditional gene expression in bacterial cells. Methods Enzymol. (2002) 358:43-66.
40. JOSENHANS C, FRIEDRICH S, SUERBAUM S: Green fluorescent protein as a novel marker and reporter system in Helicobacter sp. FEMS Microbiol. Lett. (1998) 161:263-273.
41. VALDIVIA RH, FALKOW S: Bacterial genetics by flow cytometry: rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction. Mol. Microbiol. (1996) 22(2):367-378.
42. ISRAEL DA, SALAMA N, ARNOLD CN et al.: Helicobacter pylori strain-specific differences in genetic content, identified by microarray influence host inflammatory responses. J. Clin. Invest. (2001) 107:611-620.
43. THOMPSON LJ, MERRELL DS, NEILAN BA, MITCHELL H, LEE A, FALKOW S: Gene expression profiling of Helicobacter pylori reveals growth-phase-dependent switch in virulence gene expression. Infect. Immun. (2003) 71(5):2643-2655.
44. MERRELL DS, GOODRICH ML, OTTO G, TOMPKINS LS, FALKOW S: pH-regulated gene expression of the gastric pathogen Helicobacter pylori. Infect. Immun. (2003) 71(6):3529-3539.
45. JOSENHANS C, NIEHUS E, AMERSBACH S et al.: Functional characterization of the antagonistic flagellar late regulators FliA and FlgM of Helicobacter pylori and their effects on the H. pylori transcriptome. Mol. Microbiol. (2002) 43(2):307-322.
46. WAIDNER B, MELCHERS K, IVANOV I et al.: Identification by RNA profiling and mutational analysis of the novel copper resistance determinants CrdA (HP1326), CrdB (HP1327), and CzcB (HP1328) in Helicobacter pylori. J. Bacteriol. (2002) 184(23):6700-6708.
47. CONTRERAS M, THIBERGE JM, MANDRAND-BERTHELOT MA, LABIGNE A: Characterization of the roles of NikR, a nickel-responsive pleiotropic autoregulator of Helicobacter pylori. Mol. Microbiol. (2003) 49(4):947-963.
48. THOMPSON LJ, DE REUSE H: Genomics of Helicobacter pylori. Helicobacter (2002) 7:1-7.
49. SCHOOLNIK GK: Functional and comparative genomics of pathogenic bacteria. Curr. Opin. Microbiol. (2002) 5:20-26.
50. SEPULVEDA AR, TAO H, CARLONI E, SEPULVEDA J, GRAHAM DY, PETERSON LE: Screening of gene expression profiles in gastric epithelial cells induced by Helicobacter pylori using microarray analysis. Aliment. Pharmacol. Ther. (2002) 16(2):145-157.
51. LIM JW, KIM H, KIM KH: Cell adhesion-related gene expression by Helicobacter pylori in gastric epithelia AGS cells. Int. J. Biochem. Cell Biol. (2003) 35:1284-1296.
52. JIANG W, BAKER HJ, SMITH BF: Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect. Immun. (2003) 71(1):40-46.
53. MCATEE CP, FRY KE, BERG DE: Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by 'proteome' technologies. Helicobacter (1998) 3(3):163-169.
54. MCATEE CP, LIM MY, FUNG K et al.: Characterization of a Helicobacter pylori candidate by proteome techniques. J. Chromatogr. B. Biomed. Sci. Appl. (1998) 714:325-333.
55. MCATEE CP, HOFFAMN PS, BERG DE: Identification of differentially regulated proteins in metronidazole-resistant Helicobacter pylori by proteome techniques. Proteomics (2001) 1(4):516-521.
56. JUNGBLUT PR, BUMANN D, HAAS G et al.: Comparative proteome analysis of Helicobacter pylori. Mol. Microbiol. (2000) 26(3):710-725.
57. BUMANN D, AKSU S, WENDLAND M et al.: Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect. Immun. (2002) 70(7):3396-3403.
58. HYNES SO, MCGUIRE J, WADSTROM T: Potential for proteomic profiling of Helicobacter pylori and other Helicobacter spp. using a Proteinchip® array. FFMS Immunol. Med. Microbiol. (2003) 36:151-158.
59. HYNES SO, MCGUIRE J, FALT T, WADSTROM T: The rapid detection of low molecular mass proteins differentially expressed under biological stress for four Helicobacter spp. Using Proteinchip® technology. Proteomics (2003) 3:273-278.
60. SCHMID MB: Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol. (2002) 10(10):S27-S31.
61. ABAGYAN R, TOTROV M: High-throughput docking for lead generation. Curr. Opin. Chem. Biol. (2001) 5(4):375-382.
62. RAIN JC, SELIG L, DE REUSE H et al.: The protein-protein interaction map of Helicobacter pylori. Nature (2001) 409:211-215.
63. BOCK JR, GOUGH DA: Whole-proteome interaction mining. Bioinformatics (2003) 19(1):125-135.
64. LAZOWSKA I, TRZECIAK L, GODLEWSKA R et al.: In search of immunogenic Helicobacter pylori proteins by screening of expression library. Digestion (2000) 61(1):14-21.
65. HOUIMEL M, MACH JP, CORTHESY-THEULAZ I, VORTHESY B, FISCH I: New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur. J. Biochem. (1999) 262:774-780.
66. CHRISTENSEN DJ, GOTTLIN EB, BENSON RE, HAMILTON PT: Phage display for target-based antibacterial drug discovery. Drug Discov. Today (2001) 6(14):721-727.
67. COVACCI A, RAPPUOLI R: Helicobacter pylori: after the genomes, back to biology. J. Exp. Med. (2003) 197(7):807-811.
68. HAQUE TS, TADESSE S, MARCINKEVICIENE J et al.: Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase. J. Med. Chem. (2002) 45(21):4669-4678.
69. CHUNG JG, CHEN GW, WU LT et al.: Effects of garlic compounds diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Am. J. Chin. Med. (1998) 26(3-4):353-364.
70. OHSAKI A, TAKASHIMA J, CHIBA N, KAWAMURA M: Microanalysis of a selective potent anti-Helicobacter pylori compound in a Brazillian medicinal plant, Myroxylon peruiferum and the activity of analogues. Bioorg. Med. Chem. Lett. (1999) 9(8):1109-1112.
71. MICHETTI P, KREISS C, KOTLOFF KL et al.: Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 116(4):804-812.
72. SOUGIOULTZIS S, LEE CK, ALSAHLI M et al.: Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine (2002) 21(3-4):194-201.
73. LEE CK, SOIKE K, HILL J et al.: Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine (1999) 17(17):1493-1505.
74. DIPETRILLO MD, TIBBETTS T, KLEANTHOUS H, KILLEEN KP, HOHMANN EL: Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine (1999) 18:449-459.
75. BUMANN D, METZGER WG, MANSOURI E et al.: Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine (2001) 20:845-852.
76. PRINZ C, HAFSI N, VOLAND P: Helicobacter pylori virulence factors and the host immune response: implications for therapeutic therapy. Trends Microbiol. (2003) 11(3):134-138.
77. LEE CK: Vaccination against Helicobacter pylori in non-human primate models and humans. Scand. J. Immunol. (2001) 53:437-442.
78. OHTA T, SHIBATA H, KAWAMORI T, IIMURO M, SUGIMURA T, WAKABAYASHI K: Marked reduction of Helicobacter pylori-induced gastritis by urease inhibitors, acetohydroxamic acid and flurofamide, in Mongolian gerbils. Biochem. Biophys. Res. Commun. (2001) 285:728-733.
79. SACHS G, SCOTT DR, WEEKS DL, REKTORSCHECK M, MELCHERS K: Regulation of urease for acid habitation. In: Helicobacter pylori: Physiology and Genetics. Mobley HLT, Mendz GL, Hazell SL (Eds), ASM Press, Washington DC, USA (2001)25:277-283.